Adjuvant treatment in endometrial cancer: when and what to choose

IF 0.5 4区 医学 Q4 OBSTETRICS & GYNECOLOGY European journal of gynaecological oncology Pub Date : 2022-02-15 DOI:10.31083/j.ejgo4301018
M. Paderno, T. Grassi, M. Adorni, Benedetta Zambetti, G. Di Martino, L. Bazzurini, F. Landoni, A. Lissoni
{"title":"Adjuvant treatment in endometrial cancer: when and what to choose","authors":"M. Paderno, T. Grassi, M. Adorni, Benedetta Zambetti, G. Di Martino, L. Bazzurini, F. Landoni, A. Lissoni","doi":"10.31083/j.ejgo4301018","DOIUrl":null,"url":null,"abstract":"Endometrial cancer is the most common gynecological malignancy in developed countries. The management is primarily surgical, but adjuvant treatment may be indicated after surgery, according to the risk of recurrence. This review will focus on the prognostic risk groups presented in the 2020 ESGO/ESTRO/ESP guidelines and the ongoing trials based on new molecular markers that will help to get a more personalized cancer medicine.","PeriodicalId":11903,"journal":{"name":"European journal of gynaecological oncology","volume":" ","pages":""},"PeriodicalIF":0.5000,"publicationDate":"2022-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European journal of gynaecological oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.31083/j.ejgo4301018","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Endometrial cancer is the most common gynecological malignancy in developed countries. The management is primarily surgical, but adjuvant treatment may be indicated after surgery, according to the risk of recurrence. This review will focus on the prognostic risk groups presented in the 2020 ESGO/ESTRO/ESP guidelines and the ongoing trials based on new molecular markers that will help to get a more personalized cancer medicine.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
子宫内膜癌的辅助治疗:何时以及选择什么
癌症是发达国家最常见的妇科恶性肿瘤。治疗主要是手术治疗,但根据复发风险,手术后可能需要辅助治疗。这篇综述将重点关注2020年ESGO/ESTRO/ESP指南中提出的预后风险组,以及基于新分子标记物的正在进行的试验,这些试验将有助于获得更个性化的癌症药物。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
25.00%
发文量
58
审稿时长
1 months
期刊介绍: EJGO is dedicated to publishing editorial articles in the Distinguished Expert Series and original research papers, case reports, letters to the Editor, book reviews, and newsletters. The Journal was founded in 1980 the second gynaecologic oncology hyperspecialization Journal in the world. Its aim is the diffusion of scientific, clinical and practical progress, and knowledge in female neoplastic diseases in an interdisciplinary approach among gynaecologists, oncologists, radiotherapists, surgeons, chemotherapists, pathologists, epidemiologists, and so on.
期刊最新文献
Timing and duration of bevacizumab treatment and survival in patients with recurrent ovarian, fallopian tube, and peritoneal cancer: a multi-institution study. Vulvar cancer in young woman—case report Identification of an immune-related metabolic gene signature to predict possible prognosis in endometrial cancer and reveals immune landscape feature Evaluation of colposcopy and LEEP results performed in gynecology and gynecological oncology surgery services The infrequent large pelvi-perineal tumors as a surgical dilemma: en bloc resection and long-term results
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1